Novartis AG ADR (NVS)vsPrenetics Global Ltd (PRE)
NVS
Novartis AG ADR
$147.85
+3.44%
HEALTHCARE · Cap: $282.11B
PRE
Prenetics Global Ltd
$16.71
-4.02%
HEALTHCARE · Cap: $310.15M
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 61138% more annual revenue ($56.58B vs $92.39M). NVS leads profitability with a 23.9% profit margin vs -63.1%. NVS earns a higher WallStSmart Score of 51/100 (C-).
NVS
Buy51
out of 100
Grade: C-
PRE
Avoid35
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-52.5%
Fair Value
$109.60
Current Price
$147.85
$38.25 premium
Margin of Safety
+17.4%
Fair Value
$25.92
Current Price
$16.71
$9.21 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Revenue surging 248.6% year-over-year
Reasonable price relative to book value
Areas to Watch
Expensive relative to growth rate
Grey zone — moderate risk
Revenue declined 0.7%
Earnings declined 9.3%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -31.8% — below average capital efficiency
Negative free cash flow — burning cash
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : PRE
The strongest argument for PRE centers on Revenue Growth, Price/Book. Revenue growth of 248.6% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are PEG Ratio, Altman Z-Score, Revenue Growth.
Bear Case : PRE
The primary concerns for PRE are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
NVS profiles as a declining stock while PRE is a hypergrowth play — different risk/reward profiles.
NVS carries more volatility with a beta of 0.52 — expect wider price swings.
PRE is growing revenue faster at 248.6% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
NVS scores higher overall (51/100 vs 35/100), backed by strong 23.9% margins. PRE offers better value entry with a 17.4% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Prenetics Global Ltd
HEALTHCARE · DIAGNOSTICS & RESEARCH · USA
Prenetics Global Ltd (PRE) is a premier health technology innovator focused on delivering advanced genetic and diagnostic testing solutions that empower consumers and healthcare professionals with critical health insights. With a diverse portfolio of state-of-the-art testing services and integrated digital health offerings, the company has seen significant international growth, fueled by strategic partnerships and a strong commitment to ongoing research and development. As a frontrunner in the personalized medicine space, Prenetics is ideally positioned to capitalize on the increasing demand for accessible and actionable health information, representing a compelling investment opportunity in the dynamic healthcare landscape.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?